​​Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the ASCO Annual Meeting 2023

​​Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the ASCO Annual Meeting 2023

header-info

This year at ASCO 2023, Convergent Therapeutics Inc. announced the title of an upcoming poster presentation on its lead asset, CONV01-α (225Ac-J591), a prostate-specific membrane antigen-targeted monoclonal antibody linked to actinium-225 (225Ac).

 

Access the full press release to read more here.